Jason Cohen, Editor

About the Author Jason Cohen, Editor


Global Blood Therapeutics Inc (GBT): Despite Reports of Two Patient Deaths, This Top Analyst Remains Bullish

Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.

Read more

Jason McCarthy’s Take on Gilead Sciences, Inc. (GILD) Following ASH Data

ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.

Read more

argenx SE (ARGX) Scores ASH Win in Myasthenia Gravis

The annual meeting for the American Society of Hematology (ASH) has just kicked off. Running …

Read more

Immunomedics, Inc. (IMMU): Analyst Phil Nadeau Provides Update From San Antonio Breast Cancer Symposium

Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.

Read more

This Healthcare Analyst Pounds the Table on Revance Therapeutics Inc (RVNC)

Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.

Read more

Adamis Pharmaceuticals Corp: Naloxone Could Be a Significant Growth Candidate, Says Elliot Wilbur

With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.

Read more

The Good and the Ugly Side of Biotech: Celsion Corporation (CLSN), Cytokinetics, Inc. (CYTK)

The Good: Oppenheimer Sees Celsion Corporation Shares Soaring About 180% Over 12 Months It can …

Read more

Omeros Corporation (OMER) Wows Investors with Strong Revenue Growth, But Elemer Piros Stays on the Sidelines

Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.

Read more

SAGE Therapeutics Inc (SAGE) Attains 52-Week High on Encouraging Clinical Results; Needham Cheers

Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.

Read more

Wall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price Target

The market has divided itself into two camps. The bulls argue that the worst is …

Read more